Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/31/2025

SSRI Safety with Thyroid Dysfunction and Atrial Fibrillation

Critical Management Priority: Treat the Thyroid Disorder First

  • The American College of Cardiology recommends restoring a euthyroid state, which results in spontaneous reversion to sinus rhythm in over half of patients with thyroid dysfunction and atrial fibrillation 4
  • Beta-blockers are mandatory as first-line therapy for rate control in thyrotoxic AF, providing dual benefit by controlling heart rate AND blocking peripheral conversion of T4 to T3, according to the American College of Cardiology (Class I recommendation) 1, 2, 3, 4

SSRI-Specific Considerations

  • SSRIs do not have direct contraindications with thyroid dysfunction or atrial fibrillation, but require vigilance about drug interactions with medications used to manage these conditions, as stated by the American Heart Association 2
  • Certain SSRIs can increase beta-blocker levels through CYP2D6 inhibition, requiring careful monitoring, according to the American College of Cardiology 2
  • SSRIs may have minor effects on QT interval, but this is generally not clinically significant in the absence of other risk factors, as reported by the Journal of the American College of Cardiology 1

Immediate Management Algorithm

Step 1: Rate Control

  • The American College of Cardiology recommends starting IV beta-blockers immediately if rapid ventricular response is present, exercising caution with overt congestion or hypotension 3
  • High doses may be required in severe thyrotoxicosis, according to the American College of Cardiology 3
  • If beta-blockers are contraindicated, the American Heart Association recommends using non-dihydropyridine calcium channel antagonists (diltiazem or verapamil) 1, 2

Step 2: Anticoagulation

  • The American College of Cardiology recommends initiating or continuing oral anticoagulation based on CHA₂DS₂-VASc score, NOT thyroid status 3, 4
  • Age ≥65 years or heart failure alone mandates anticoagulation (CHA₂DS₂-VASc ≥2), according to the American Heart Association 3
  • The American College of Cardiology recommends targeting INR 2.0-3.0 with warfarin, or using direct oral anticoagulants 3

Step 3: Thyroid Treatment

  • The American Thyroid Association recommends beginning antithyroid therapy immediately to restore euthyroid state, although the exact citation is not provided
  • Do NOT attempt cardioversion or use antiarrhythmic drugs until euthyroid state is achieved, as they are generally unsuccessful while thyrotoxicosis persists, according to the American College of Cardiology 3, 4
  • Defer cardioversion until approximately 4 months after maintaining euthyroid state, as recommended by the American Thyroid Association 3, 4

Step 4: SSRI Initiation (if indicated for depression/anxiety)

  • Select an SSRI with minimal CYP2D6 inhibition if patient is on beta-blockers, such as sertraline, citalopram, or escitalopram, as recommended by the American Psychiatric Association 3
  • Start at lower doses and titrate carefully while monitoring heart rate and rhythm, according to the American College of Cardiology 5
  • Monitor for any worsening of AF symptoms or inadequate rate control, as stated by the Journal of the American College of Cardiology 1

Critical Pitfalls to Avoid

  • Never use digoxin as monotherapy for acute rate control in thyrotoxic AF, as it is less effective in hyperthyroid states, according to the American College of Cardiology 3, 5
  • Never use amiodarone in patients with active hyperthyroidism due to risk of fatal thyroid storm, as warned by the American Thyroid Association 3, 4
  • Never withhold anticoagulation based solely on hyperthyroidism—use CHA₂DS₂-VASc score to determine anticoagulation needs, according to the American Heart Association 3
  • Never attempt rhythm control before achieving euthyroid state, as cardioversion and antiarrhythmic drugs fail while thyrotoxicosis persists, as stated by the American College of Cardiology 3, 4

Monitoring During SSRI Therapy

  • Monitor thyroid function tests regularly, as achieving and maintaining euthyroid state is essential, according to the American Thyroid Association 4
  • Target TSH in normal reference range, as recommended by the American Thyroid Association 4
  • Assess heart rate during exercise and adjust pharmacological treatment in symptomatic patients, according to the American Heart Association 2
  • Continue anticoagulation based on CHA₂DS₂-VASc score even after achieving euthyroid state, as recommended by the American College of Cardiology 3, 4

Long-Term Considerations

  • SSRIs can be continued long-term as long as thyroid function remains stable and AF is adequately controlled, according to the American Psychiatric Association 4